135 related articles for article (PubMed ID: 10470203)
1. Serum tissue polypeptide antigen (TPA): monoclonal or polyclonal radio-immunometric assay for the follow-up of bladder cancer.
Bennink R; Van Poppel H; Billen J; Decoster M; Baert L; Mortelmans L; Blanckaert N
Anticancer Res; 1999; 19(4A):2609-13. PubMed ID: 10470203
[TBL] [Abstract][Full Text] [Related]
2. Clinical relevance of CYFRA 21-1, TPA-IRMA and TPA-LIA-mat in urinary bladder cancer.
Stieber P; Schmeller N; Schambeck C; Hofmann K; Reiter W; Hasholzner U; Fateh-Moghadam A
Anticancer Res; 1996; 16(6B):3793-8. PubMed ID: 9042259
[TBL] [Abstract][Full Text] [Related]
3. Serum tissue polypeptide antigen (TPA) as tumor marker for bladder cancer.
van Poppel H; Billen J; Goethuys H; Elgamal AA; Gerits M; Mortelmans L; Blanckaert N; Baert L
Anticancer Res; 1996; 16(4B):2205-7. PubMed ID: 8694544
[TBL] [Abstract][Full Text] [Related]
4. Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancer.
Ecke TH; Lenk SV; Schlechte HH; Loening SA
Anticancer Res; 2003; 23(2A):957-62. PubMed ID: 12820330
[TBL] [Abstract][Full Text] [Related]
5. [Cytokeratin tumor markers in ovarian carcinoma: tissue polypeptide specific antigen (TPS) and M3/M21].
Hefler L; Tempfer C; Häusler G; Heinzl H; Kainz C
Wien Klin Wochenschr; 1998 Oct; 110(18):635-41. PubMed ID: 9816636
[TBL] [Abstract][Full Text] [Related]
6. [Diagnostic value of tissue polypeptide antigen in serum of larynx cancer patients].
Polberg K; Stepulak A; Stryjecka-Zimmer M; Kupisz K; Zawiślak J
Pol Merkur Lekarski; 2005 Oct; 19(112):517-20. PubMed ID: 16379315
[TBL] [Abstract][Full Text] [Related]
7. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
[TBL] [Abstract][Full Text] [Related]
8. Tissue polypeptide antigen in the follow-up of patients with urinary bladder cancer compared with conventional urine cytology.
Bantis A; Zissimopoulos A; Sountoulides P; Giannakopoulos S; Kalaitzis C; Athanassiadou P; Agelonidou E; Touloupidis S
Hell J Nucl Med; 2010; 13(3):213-7. PubMed ID: 21193872
[TBL] [Abstract][Full Text] [Related]
9. [Tissue polypeptide antigen (TPA)].
Sugiyama Y; Kawaguchi Y
Nihon Rinsho; 2005 Aug; 63 Suppl 8():705-7. PubMed ID: 16149617
[No Abstract] [Full Text] [Related]
10. Comparison between tissue antigen analysis and plasma determinations for TPA and CEA in transitional cell carcinomas and in tumorfree urothelium of the urinary bladder.
Vogel J; Oehr P; Maisey R; Adolphs HD
Cancer Detect Prev; 1988; 11(3-6):389-96. PubMed ID: 2455597
[TBL] [Abstract][Full Text] [Related]
11. [Measurement of serum tissue polypeptide antigen (TPA) in patients with malignant tumor using prolifigen TPA-M "Daiichi" kit].
Sakahara H; Endo K; Torizuka K; Itoh K; Ohuchi N; Inaba N; Miyaji Y; Takayama M; Ishii K; Takagi H; Konishi J; Fukuoka M; Fukuchi M; Ohkawa J; Kagawa S; Kondo S; Shirouzu K; Iguchi H
Gan To Kagaku Ryoho; 1996 May; 23(6):733-43. PubMed ID: 8645025
[TBL] [Abstract][Full Text] [Related]
12. Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation.
Ecke TH; Schlechte HH; Schulze G; Lenk SV; Loening SA
Anticancer Res; 2005; 25(1B):635-41. PubMed ID: 15816639
[TBL] [Abstract][Full Text] [Related]
13. [Serum and tissue quantification of tissue polypeptide antigen (TPA) in transitional cell carcinoma of the bladder].
Moreno Sierra J; Maestro de las Casas ML; Ortega Heredia MD; Blanco Jimenez E; Hermida Gutiérrez J; Resel Estévez L
Arch Esp Urol; 1994 Dec; 47(10):979-84. PubMed ID: 7864679
[TBL] [Abstract][Full Text] [Related]
14. TPA prognostic value in superficial bladder cancer.
Filella X; Menendez V; Molina R; Alcover J; Carretero P; Ballesta AM
Anticancer Res; 1996; 16(4B):2173-5. PubMed ID: 8694539
[TBL] [Abstract][Full Text] [Related]
15. Serum biomarkers facilitate the recognition of early- stage cancer and may guide the selection of surgical candidates: a study of carcinoembryonic antigen and tissue polypeptide antigen in patients with operable non-small cell lung cancer.
Buccheri G; Ferrigno D
J Thorac Cardiovasc Surg; 2001 Nov; 122(5):891-9. PubMed ID: 11689793
[TBL] [Abstract][Full Text] [Related]
16. [Significance of combined determination of CK19mRNA, carcinoembryanic antigen, neuron-specific enolase, and tissue polypeptide antigen in peripheral blood of patients with lung cancer].
Pan QR; Zhang X; Xu ZF; Zheng S
Ai Zheng; 2002 Feb; 21(2):196-9. PubMed ID: 12479076
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of tissue polypeptide antigen (TPA) plasma levels in patients with malignant salivary gland tumors.
Tanany H; Ezz M; Yassin S
Egypt Dent J; 1993 Jul; 39(3):505-6. PubMed ID: 9590978
[TBL] [Abstract][Full Text] [Related]
18. Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?
Gaarenstroom KN; Kenter GG; Bonfrer JM; Korse CM; Van de Vijver MJ; Fleuren GJ; Trimbos JB
Gynecol Oncol; 2000 Apr; 77(1):164-70. PubMed ID: 10739706
[TBL] [Abstract][Full Text] [Related]
19. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.
Fernandez-Gomez J; Rodríguez-Martínez JJ; Barmadah SE; García Rodríguez J; Allende DM; Jalon A; Gonzalez R; Alvarez-Múgica M
Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912
[TBL] [Abstract][Full Text] [Related]
20. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
